Intracellular IFN-γ and IL-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients

Cytokine

Volumn 61, Issue 2, 2013, Pages 556-564

  Millan O ^a,b   Rafael Valdivia, L ^c   Torrademe E ^a   Lopez A ^a   Fortuna, V ^a   Sanchez Cabus S ^c   Lopez Pua Y ^c   Rimola, A ^b,c   Brunet, M ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Acute rejection; IFN and IL 2; Liver transplantation; Personal drug response; Surrogate marker

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; LIVER TRANSPLANTATION; MALE; MONITORING; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; DEMOGRAPHY; DISEASE SUSCEPTIBILITY; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-2; INTRACELLULAR SPACE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; RISK FACTORS; SOLUBILITY; TACROLIMUS; TREATMENT OUTCOME;

EID: 84873150010     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.10.026     Document Type: Article

References (24)

1. Benseler V., McCaughan G.W., Schlitt H.J., et al. The liver: a special case in transplant tolerance. Semin Liver Dis 2007, 27:94-213.
2. Strom T.B., Tilney N.L., Carpenter C.B., et al. Identity and cytotoxic capacity of cells infiltrating renal allografts. N Engl J Med 1975, 292:1257-1263.
3. Benítez F., Najafian N. Novel noninvasive assays to predict transplantation rejection and tolerance. enumeration of cytokine-producing alloreactive T cells. Clin Lab Med 2008, 28:365-373.
4. Le Moine A., Goldman M., Abramowicz D. Multiple pathways to allograft rejection. Transplantation 2002, 73:1373-1381.
5. Fontenot J.D., Rasmussen J.P., Gavin M.A., et al. A function for interleukin-2 in FOXP3-expressing regulatory T cells. Nat Immunol 2005, 6:1142-1151.
6. Rosenzweig S.D., Holland S.M. Defects in the interferon-gamma and interleukin-12 pathways. Immunol Rev 2005, 203:38-47.
7. Maecker H.T., McCoy J.P. A model for harmonization flow cytometry in clinical trials. Nat Immunol 2010, 11:200-975.
8. Nickel P., Presber F., Bold G., et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12months in renal-transplant recipients. Transplantation 2004, 78:1640-1646.
9. Kim S.H., Oh E.J., Kim M.J., et al. Pretransplant donor-specific interferon-gamma ELISPOT assay predicts acute rejection episodes in renal transplant recipients. Transplant Proc 2007, 39:3057-3060.
10. Bestard O., Nickel P., Cruzado J.M., et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol 2008, 19(7):1419-1429.
11. Okanami Y., Tsujimura K., Mizuno S., et al. Intracellular interferon-γ staining analysis of donor-specific T-cell responses in liver transplant recipients. Transplant Proc 2012, 44(2):548-554.
12. Millán O., Benitez C., Guillen D., et al. Biomarkers of immunosuppression status in liver transplant recipients undergoing weaning of immunosuppressive therapy. Clin Immunol 2010, 137:337-346.
13. + T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation 2004, 77:1815-1820.
14. Akoglu B., Kriener S., Martens S., et al. Interleukin-2 in CD8+ T cells correlates with Banff score during organ rejection in liver transplant recipients. Clin Exp Med 2009, 9(4):259-262.
15. Barten M.J., Rahmel A., Garbade J., et al. Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients. Transplant Proc 2005, 37(10):4532-4534.
16. Ahmed M., Venkataraman R., Logar A.J., et al. Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells. Ther Drug Monit 2001, 23:354-362.
17. Guillen D, Millán O, Rimola A, Brunet M. Specific method for simultaneous determination of calcineurin and mTOR inhibitor immunosuppressants in human whole blood by LC/MS/MS. J Chromat B, submitted for publication.
18. Brunet M., Cirera I., Martorell J., Vidal E., Millán O., Jiménez O., et al. Sequential determination of pharmacokinetics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation 2006, 81:541-546.
19. Grinyó J.M., Ekberg H., Mamelok R.D., et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transplant 2009, 24(7):2269-2276.
20. Wieland E., Olbricht C.J., Süsal C., et al. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit 2010, 72:560-572.
21. Brunet M., Campistol J.M., Diekmann F., Guillen D., Millán O. T-cell function monitoring in stable renal transplant patients treated with sirolimus monotherapy. Mol Diagn Ther 2007, 11:247-256.
22. Reinsmoen N.L., Cornett K.M., Kloehn R., et al. Pretransplant donor-specific and non-specific immune parameters associated with early acute rejection. Transplantation 2008, 85:462-470.
23. Kowalski R.J., Post D.R., Mannon R.B., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006, 82:663-668.
24. Heeger P.S., Greenspan N.S., Kuhlenschmidt S., et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999, 163:2267-2275.